Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022
bởiAudrey Abella
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
30 Dec 2021
bởiAudrey Abella
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.